British Journal of Anaesthesia, 2002, Vol. 88, No. 2 159-163
© 2002 The Board of Management and Trustees of the British Journal of Anaesthesia
Editorial |
Editorial I
Is there a bleeding problem with platelet-active drugs?
Platelets provide for primary haemostasis by forming a plug at sites of vascular damage. After initial adhesion, platelets aggregate to effect haemostatic plug formation. Platelet aggregation requires active platelet metabolism; stimulation by agonists such as adenosine diphosphate (ADP) or thrombin; divalent cations; specific plasma proteins such as fibrinogen; and a platelet receptor, the glycoprotein IIb/IIIa (GP IIb/IIIa) complex. Activation of the GP IIb/IIIa receptor on the platelet surface is the final pathway of platelet aggregation, regardless of the initiating stimulus. During aggregation, ADP is released from the platelet to autoactivate its own receptor, thromboxane A2 (TxA2) is synthesized, and preformed serotonin is released to promote microvascular constriction, helping the plug to form a more solid hold on wound edges.
Platelet-active medications have diverse mechanisms of action, pharmacodynamic and adverse effect profiles. All the current drugs can prolong the skin bleeding time. One of the perceived risks of platelet active
Non-steroidal anti-inflammatory drugs (NSAIDs)
Spontaneous bleeding
Surgical bleeding
Specific therapy to reduce bleeding
Purinergic or adenosine diphosphate receptor blockers
Spontaneous bleeding
Surgical bleeding
Specific therapy to reduce bleeding
Platelet glycoprotein receptor (GPIIb/IIIa) antagonists
Spontaneous bleeding
Surgical bleeding
Specific therapy to reduce bleeding
References
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Bengeri, S. Bolsin, L. Broad, M. Conroy, S. Black, N. Orford, and G. Birdsey Successful management of patients with a drug-eluting coronary stent presenting for elective surgery Br. J. Anaesth., June 1, 2007; 98(6): 841 - 842. [Full Text] [PDF] |
||||
![]() |
G. M. Howard-Alpe, J. de Bono, L. Hudsmith, W. P. Orr, P. Foex, and J. W. Sear Coronary artery stents and non-cardiac surgery Br. J. Anaesth., May 1, 2007; 98(5): 560 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Scharbert, E. Deusch, H. G. Kress, M. Greher, B. Gustorff, and S. A. Kozek-Langenecker Inhibition of Platelet Function by Hydroxyethyl Starch Solutions in Chronic Pain Patients Undergoing Peridural Anesthesia Anesth. Analg., September 1, 2004; 99(3): 823 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Horlocker, Z. H. Bajwa, Z. Ashraf, S. Khan, J. L. Wilson, N. Sami, C. Peeters-Asdourian, C. A. Powers, D. R. Schroeder, P. A. Decker, et al. Risk Assessment of Hemorrhagic Complications Associated with Nonsteroidal Antiinflammatory Medications in Ambulatory Pain Clinic Patients Undergoing Epidural Steroid Injection Anesth. Analg., December 1, 2002; 95(6): 1691 - 1697. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Innerhofer, D. Fries, J. Margreiter, A. Klingler, G. Kuhbacher, B. Wachter, E. Oswald, E. Salner, B. Frischhut, and W. Schobersberger The Effects of Perioperatively Administered Colloids and Crystalloids on Primary Platelet-Mediated Hemostasis and Clot Formation Anesth. Analg., October 1, 2002; 95(4): 858 - 865. [Abstract] [Full Text] [PDF] |
||||

